A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients

Adv Neurol. 1996:69:531-4.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / therapeutic use*
  • Dopamine Agonists / administration & dosage
  • Dopamine Agonists / adverse effects
  • Dopamine Agonists / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Indoles / administration & dosage
  • Indoles / adverse effects
  • Indoles / therapeutic use*
  • Levodopa / therapeutic use
  • Movement Disorders / drug therapy*
  • Movement Disorders / physiopathology
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Receptors, Dopamine D2 / agonists*

Substances

  • Antiparkinson Agents
  • Dopamine Agonists
  • Indoles
  • Receptors, Dopamine D2
  • ropinirole
  • Levodopa